Karin Hoelzer’s Post

At this year’s World Orphan Drug Congress Europe, Clinigen’s Working Group explored the progress and challenges surrounding EU orphan drug legislation. With over 205 treatments approved since 2000, we’ve seen incredible strides in addressing rare diseases. Yet, there is more to be done. Proposed legislative changes aim to tackle unmet medical needs, affordability, and innovation barriers but raise concerns about reduced incentives for drug development. At Clinigen, we’re committed to collaborating with all stakeholders to bridge gaps and support solutions that deliver life-changing treatments to patients in need. Read more about Elizabeth Taylor’s key takeaways and insights: https://lnkd.in/gQhXBc-H #WorldOrphanDrugCongress #RareDisease #PatientAccess #LifeSciences #Clinigen #Kinesys #WODC #PharmaNetworking #PatientAdvocacy

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.